# Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-23-032-late-stage-translation-of-biomedical-and-behavioral-research/  
Official notice: https://www.grants.gov/search-results-detail/344212

> National Institutes of Health offered grants of up to $350,000 to small businesses. Applications closed on September 5, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-23-032 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 5, 2025 |
| Award ceiling | $350,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.846 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

## Questions people ask

### Is PAR-23-032 still open?

No. It closed on September 5, 2025.

### Who can apply for Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)?

Closed September 5, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $350,000 each.

### Who has been funded under PAR-23-032?

NIH RePORTER lists 8 projects funded under PAR-23-032 in fiscal 2023 to 2026, at 6 institutions. The most were at Collamedix Inc., Tissuerate Inc., MDS II LLC.

### Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, The Regents of the University of California, San Francisco. The program made 2,897 awards worth $2.6 billion in that time.